$5.625
0.095[1.72%]
At close: Apr 17
$5.625
0[0.00%]
After Hours: 4:00PM EDT
Health Catalyst
(NASDAQ:HCAT)Health Catalyst Stock (NASDAQ:HCAT), Analyst Ratings, Price Targets, Predictions
Health Catalyst Inc has a consensus price target of $18.11, established from looking at the 63 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Keybanc, and Cantor Fitzgerald on April 10, 2024, April 10, 2024, and March 5, 2024. With an average price target of $10.67 between Cantor Fitzgerald, Keybanc, and Cantor Fitzgerald, there's an implied 89.63% upside for Health Catalyst Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Keybanc
Piper Sandler
Evercore ISI Group
Canaccord Genuity
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Health Catalyst
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 184.44% | Cantor Fitzgerald | Sarah James | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 04/10/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | — | Keybanc | Scott Schoenhaus | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 03/05/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 184.44% | Cantor Fitzgerald | Sarah James | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 02/26/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 77.78% | Keybanc | Scott Schoenhaus | $12 → $10 | Maintains | Overweight | Get Alert |
| 02/23/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 166.67% | Piper Sandler | Jessica Tassan | $17 → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 77.78% | Evercore ISI Group | Elizabeth Anderson | $11 → $10 | Maintains | Outperform | Get Alert |
| 02/23/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 95.56% | Canaccord Genuity | Richard Close | $12 → $11 | Maintains | Buy | Get Alert |
| 01/26/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 148.89% | Guggenheim | Jack Wallace | → $14 | Upgrade | Neutral → Buy | Get Alert |
| 01/03/2024 | HCAT | Buy Now | Health Catalyst | $5.63 | 95.56% | Evercore ISI Group | Elizabeth Anderson | $9 → $11 | Upgrade | In-Line → Outperform | Get Alert |
| 12/22/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 113.33% | Piper Sandler | Jessica Tassan | $11 → $12 | Maintains | Overweight | Get Alert |
| 12/13/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 95.56% | JP Morgan | Anne Samuel | $14 → $11 | Upgrade | Neutral → Overweight | Get Alert |
| 11/13/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 95.56% | Piper Sandler | Jessica Tassan | $12 → $11 | Upgrade | Neutral → Overweight | Get Alert |
| 11/01/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 113.33% | Stifel | David Grossman | $15 → $12 | Maintains | Hold | Get Alert |
| 10/30/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 42.22% | RBC Capital | Sean Dodge | $13 → $8 | Maintains | Sector Perform | Get Alert |
| 09/14/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 184.44% | Cantor Fitzgerald | Steven Halper | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 148.89% | Canaccord Genuity | Richard Close | $16 → $14 | Maintains | Buy | Get Alert |
| 08/01/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 184.44% | Cantor Fitzgerald | Steven Halper | → $16 | Initiates | Overweight → Overweight | Get Alert |
| 05/10/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | 131.11% | RBC Capital | Sean Dodge | $15 → $13 | Maintains | Sector Perform | Get Alert |
| 05/10/2023 | HCAT | Buy Now | Health Catalyst | $5.63 | — | Raymond James | John Ransom | — | Downgrade | Strong Buy → Market Perform | Get Alert |
FAQ
What is the target price for Health Catalyst (HCAT)?
The latest price target for Health Catalyst (NASDAQ: HCAT) was reported by Cantor Fitzgerald on April 10, 2024. The analyst firm set a price target for $16.00 expecting HCAT to rise to within 12 months (a possible 184.44% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Health Catalyst (HCAT)?
The latest analyst rating for Health Catalyst (NASDAQ: HCAT) was provided by Cantor Fitzgerald, and Health Catalyst reiterated their overweight rating.
When was the last upgrade for Health Catalyst (HCAT)?
The last upgrade for Health Catalyst Inc happened on January 26, 2024 when Guggenheim raised their price target to $14. Guggenheim previously had a neutral for Health Catalyst Inc.
When was the last downgrade for Health Catalyst (HCAT)?
The last downgrade for Health Catalyst Inc happened on April 10, 2024 when Keybanc changed their price target from N/A to N/A for Health Catalyst Inc.
When is the next analyst rating going to be posted or updated for Health Catalyst (HCAT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Health Catalyst, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Health Catalyst was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Health Catalyst (HCAT) correct?
While ratings are subjective and will change, the latest Health Catalyst (HCAT) rating was a reiterated with a price target of $0.00 to $16.00. The current price Health Catalyst (HCAT) is trading at is $5.63, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.